ClinicalTrials.gg
RecruitingNCT06283758Updated Jan 23, 2026

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)

An interventional study of focused power ultrasound mediate inferior perirenal adipose tissue modification and Sham-control group in Hypertension, Blood Pressure and Cardiovascular Diseases, sponsored by Suzhou Municipal Hospital. Recruiting at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Suzhou Municipal Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
274th of 308
30 · median 253
Started
2024
with 29 others
No phase
146 of 410
56 open now
Primary completion
2026-07
later than 45 of 147 live
Registered
289th of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 274th largest by planned enrollment of the 308 interventional ones that give a count, is one of 30 that started in 2024, is one of 146 with no phase, reaches primary completion later than 45 of the 147 other live ones, and was the 289th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

This seamless two-stage phase II/III clinical trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension. Stage 1 is a phase II, multicenter, open-label, randomized trial to determine the optimal treatment strategy. Stage 2 is a phase III, multicenter, randomized, double-blind trial investigating the efficacy and safety of optimal treatment strategy compared to sham control.

Read the detailed description

The increase of visceral fat is closely related to the occurrence of hypertension, and it is one of the main independent risk factors of hypertension. Visceral fat has been recognized as an important endocrine organ, and a variety of factors secreted by visceral fat lead to an increased risk of cardiovascular disease. Peri-renal fat is a special type of visceral fat which is different from other type of visceral fat in histology, physiology, and functions. The positon of peri-renal fat is more stable than other visceral fat, which might be influenced by breath or body position changes. Studies have found that perirenal fat is an early predictor of ASCVD, and its accumulation is closely related to the occurrence and development of ASCVD. Therefore, the reduction or modification of visceral fat, especially peri-renal fat, has a sufficient scientific basis for the treatment of hypertension.

In the investigators' previous experiments, this novel focused power ultrasound can rapidly and efficiently promote the perirenal adipose tissue fibrosis and control the blood pressure in the model of swine. Moreover, the investigators performed a single arm, small sample study to investigate the feasibility of the novel focused power ultrasound to modify the inferior perirenal adipose tissue in human volunteers, showing that this kind of method was feasible and safe.

This seamless two-stage phase II/III clinical trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension. In Stage 1, 30 participants will be 1:1:1 randomly allocated to 3 intervention groups (single treatment group, consecutive treatment group A, and consecutive treatment group B). The optimal treatment strategy will be selected based on the decrease of blood pressure and safety evaluation and proceed to Stage 2. In Stage 2, participants will be randomly assigned to intervention group (optimal treatment strategy selected formerly in Stage 1) and sham control group.

03

Conditions studied

  • Hypertension
  • Blood Pressure
  • Cardiovascular Diseases

Keywords

  • Hypertension
  • Cardiovascular diseases
  • Focused ultrasound
  • Novel method
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individual with office systolic blood pressure (SBP) ≥ 140 mmHg and \<160 mmHg, and office diastolic blood pressure (DBP)\<100mmHg after standardized antihypertensive drug treatment for 1 month;
  2. Individual with 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average systolic blood pressure (ASBP) ≥130 mmHg;
  3. The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm;
  4. Individual is willing to sign the of the study.

Exclusion criteria

Exclusion Criteria:

  1. Individual diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome);
  2. Individuals with ≥ 3 cardiovascular risk factors (male>55 years old, female>65 years old; smoking or passive smoking; 2-hour postprandial blood glucose 7.8-11mmol/L and/or impaired fasting glucose (6.1-6.9mmol/L); LDL-C ≥ 3.4mmol/L (130mg/dl), HDL-C\<1.0mmol/L (40mg/dl) or TC ≥ 5.2mmol/L (200mg/dl); Family history of early onset of cardiovascular disease, age of onset of first degree relatives\<50 years old; Abdominal obesity, waist circumference: male>90cm, female>85cm or >28kg/m2) or hypertensive target organ damage;
  3. riser hypertension (defined as night blood pressure higher than daytime blood pressure by ABPM)
  4. Regular night shift workers
  5. Individuals taking other medications that may affect blood pressure (such as );
  6. Individual with history of kidney or kidney surrounding tissue surgery;
  7. Individuals with impairment of liver or kidney function (, AST or creatinine greater than 2 times of the reference);
  8. Individual with myocardial infarction, unstable angina pectoris, cerebrovascular accident or within 6 months of enrollment;
  9. Individual with type 1 diabetes or uncontrolled type 2 diabetes;
  10. Individual with uncontrolled thyroid dysfunction;
  11. Individual with urinary calculi or hematuria;
  12. Individual with atrial fibrillation;
  13. Individual with severe structural heart disease (e.g. valvular heart disease, cardiomyopathy, congenital heart disease);
  14. Individual with second degree and above atrioventricular block and/or sick sinus syndrome;
  15. Individual with abnormal coagulation function;
  16. Individual with infected waist skin;
  17. Individual with claustrophobia;
  18. Individual with malignant tumor;
  19. History of allergy to amlodipine, olmesartan, and hydrochlorothiazide
  20. Individual is pregnant, nursing or planning to be pregnant;
  21. Individual is unwilling to sign ;
  22. Individual fails to complete the screening period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Stage 1: Intervention group

    This arm is combined with 3 groups and a total of 30 participants will be 1:1:1 allocated (each group with 10 participants). Single treatment group: receive treatment once after enrollment; Consecutive treatment group A: receive 3 consecutive treatments, each with an interval of 3 days; Consecutive treatment group B: receive 3 consecutive treatments, each with an interval of 7 days. In Stage 1, the investigators will select optimal treatment strategy and proceed to Stage 2.

    Device: focused power ultrasound mediate inferior perirenal adipose tissue modification

  • Active comparator
    Stage 2: Intervention group

    Participants will receive optimal treatment strategy selected formerly in Stage 1

    Device: focused power ultrasound mediate inferior perirenal adipose tissue modification

  • Sham comparator
    Stage 2: Sham-control group

    In sham control group, participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.

    Device: Sham-control group

Interventions

  • Devicefocused power ultrasound mediate inferior perirenal adipose tissue modification

    This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small "cigar"-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.

  • DeviceSham-control group

    Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.

06

What researchers measure

Primary outcomes

  1. Ambulatory Blood Pressure

    Changes of mean systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 1-month compared with baseline

    Time frame: From baseline to 1 month post-procedure

Secondary outcomes

  1. Ambulatory Blood Pressure

    Changes of mean systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 3-month compared with baseline

    Time frame: From baseline to 3 month post-procedure

  2. Office Systolic Blood Pressure

    Changes of office systolic blood pressure at 1-month compared with baseline

    Time frame: From baseline to 1 month post-procedure

  3. Office Systolic Blood Pressure

    Changes of office systolic blood pressure at 3-month compared with baseline

    Time frame: From baseline to 3 month post-procedure

  4. Ambulatory Blood Pressure

    Changes of mean diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 1-month compared with baseline

    Time frame: From baseline to 1 month post-procedure

  5. Ambulatory Blood Pressure

    Changes of mean diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 3-month compared with baseline

    Time frame: From baseline to 3 month post-procedure

  6. Home Blood Pressure

    Changes of home blood pressure at 1-month compared with baseline

    Time frame: From baseline to 1 month post-procedure

  7. Home Blood Pressure

    Changes of home blood pressure at 3-month compared with baseline

    Time frame: From baseline to 3 month post-procedure

  8. Blood pressure control rate

    The control rate of blood pressure (defined as office systolic blood pressure\<140/90mmHg) at 3-month

    Time frame: From baseline to 3 month post-procedure

  9. Antihypertensive drug load index

    Changes of antihypertensive drug load index at 1-month and 3-month compared with baseline

    Time frame: From baseline to 1 month and 3 month post-procedure

Other outcomes

  1. Incidence of adverse events

    Any adverse events (AE) or severe adverse events (SAE) related to intervention. The SAE were defined as acute renal failure, acute intestinal perforation, and thromboembolic events, et al.

    Time frame: From baseline to 3 month post-procedure

07

Study locations

4 of 4 sites recruiting
  • The Affiliated Jiangning Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210000, China
    Recruiting
    • Yuqing Zhang · Contact13851672168
    • Qin Tao · Contact1585062208
    • Yuqing Zhang · Principal investigator
  • The first Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210000, China
    Recruiting
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu 210000, China
    Recruiting
    • Hongzhuan Sheng · Contact13515203348
    • Jian Zhuo · Contact18206297131
    • Hongzhuan Sheng · Principal investigator
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu 210000, China
    Recruiting
08

References and documents

Publications

  • Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med. 2004 Jun 15;140(12):992-1000. doi: 10.7326/0003-4819-140-12-200406150-00008. PubMed 15197016 ↗
  • Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR, Khera A, McGuire DK, de Lemos JA, Turer AT. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. J Am Coll Cardiol. 2014 Sep 9;64(10):997-1002. doi: 10.1016/j.jacc.2014.05.057. PubMed 25190234 ↗
  • Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci. 2005 Dec;330(6):280-9. doi: 10.1097/00000441-200512000-00005. PubMed 16355012 ↗
  • Li P, Liu B, Wu X, Lu Y, Qiu M, Shen Y, Tian Y, Liu C, Chen X, Yang C, Deng M, Wang Y, Gu J, Su Z, Chen X, Zhao K, Sheng Y, Zhang S, Sun W, Kong X. Perirenal adipose afferent nerves sustain pathological high blood pressure in rats. Nat Commun. 2022 Jun 6;13(1):3130. doi: 10.1038/s41467-022-30868-6. PubMed 35668093 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jul 2026, 28 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 28 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Feb 28, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Oct 2026
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06283758
Lead sponsor
Suzhou Municipal Hospital
Collaborators
The Affiliated Jiangning Hospital of Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Affiliated Hospital of Nantong University
Responsible party
Yanhui Sheng (Professor in Department of Cardiovascular medicine, Suzhou Municipal Hospital) — Principal investigator
First posted
Feb 28, 2024
Start date
Mar 1, 2024
Primary completion
Jul 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jan 23, 2026

Study contacts

Yanhui Sheng
Contact
yhsheng@njmu.edu.cn
13851647530
Yang Hua
Contact
759150674@qq.com
13851624359

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion